Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Panoskaltsis-Mortari, Angela  [Clear All Filters]
2024
Saha A, Palchaudhuri R, Lanieri L, Hyzy S, Riddle MJ, Panthera J, Eide C, Tolar J, Panoskaltsis-Mortari A, Gorfinkel L, et al. Alloengraftment without significant toxicity or GVHD in CD45 antibody-drug conjugate conditioned Fanconi anemia mice. Blood. 2024.
2022
Zaiken MC, Flynn R, Paz KG, Rhee SY, Jin S, Mohamed FA, Saha A, Thangavelu G, Park PMC, Hemming ML, et al. BET-bromodomain and EZH2 inhibitor treated chronic GVHD mice have blunted germinal centers with distinct transcriptomes. Blood. 2022.
Saha A, Hyzy S, Lamothe TLaforest, Hammond KJ, Clark NM, Lanieri L, Bhattarai PRaj, Palchaudhuri R, Gillard GO, Proctor J, et al. CD45-targeted antibody-drug-conjugate successfully conditions for allogeneic hematopoietic stem cell transplantation. Blood. 2022.
Mo F, Watanabe N, Omdahl KIngersoll, Burkhardt PM, Ding X, Hayase E, Panoskaltsis-Mortari A, Jenq RR, Heslop HE, Kean LS, et al. Engineering T cells to suppress acute GvHD and leukemia relapse after allogeneic hematopoietic stem cell transplantation. Blood. 2022.
Ramos TLopes, Bolivar-Wagers S, Jin S, Thangavelu G, Simonetta F, Lin P-Y, Hirai T, Saha A, Koehn BH, Su LL, et al. Prevention of acute GVHD disease using an orthogonal IL-2/IL-2Rβ system to selectively expand regulatory T-cells in vivo. Blood. 2022.
2019
Newell LF, DeFor TE, Cutler C, Verneris MR, Blazar BR, Miller JS, Antin JH, Howard A, Wu J, MacMillan ML, et al. Follistatin and Soluble Endoglin Predict 1-year Non-Relapse Mortality after Allogeneic Hematopoietic Cell Transplant. Biol Blood Marrow Transplant. 2019.
2016
Ikonomou L, Freishtat RJ, Wagner DE, Panoskaltsis-Mortari A, Weiss DJ. The Global Emergence of Unregulated Stem Cell Treatments for Respiratory Diseases. Professional Societies Need to Act. Ann Am Thorac Soc. 2016;13(8):1205-1207.
Hippen KL, Watkins B, Tkachev V, Lemire AM, Lehnen C, Riddle MJ, Singh K, Panoskaltsis-Mortari A, Vanhove B, Tolar J, et al. Preclinical testing of anti-human CD28 Fab' antibody in a novel nonhuman primate (NHP) small animal rodent model of xenogenic graft-versus-host disease (GVHD). Transplantation. 2016.
Bhargava M, Viken KJ, Dey S, Steinbach MS, Wu B, Jagtap PD, Higgins L, Panoskaltsis-Mortari A, Weisdorf DJ, Kumar V, et al. Proteome Profiling in Lung Injury Following Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2016.
McDonald-Hyman C, Flynn R, Panoskaltsis-Mortari A, Peterson N, MacDonald KPA, Hill GR, Luznik L, Serody JS, Murphy WJ, Maillard I, et al. Therapeutic regulatory T-cell adoptive transfer ameliorates established murine chronic GVHD in a CXCR5 dependent manner. Blood. 2016.
2014
Dubovsky JA, Flynn R, Du J, Harrington BK, Zhong Y, Kaffenberger B, Yang C, Towns WH, Lehman A, Johnson AJ, et al. Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. J Clin Invest. 2014.